Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its business prospects and relationship with Moderna during the specified Class Period from February 6, 2024, to September 26, 2024 [1]. Company Overview - Metagenomi is a genetic medicines company based in Emeryville, CA, with a significant collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The collaboration included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs [3]. IPO and Stock Performance - Metagenomi completed its initial public offering (IPO) on February 13, 2024, selling 6.25 million shares at 7.04 to 2.00 at the time of the lawsuit filing [5].
DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024